What Does It Mean To Be a Christian Woman? Sustaining and Empowering the Female Christian Faith in Light of Sexism in Christian Communities

What helps young Christian women sustain their faith in the face of sexism within Christian communities? Are there practices or traditions that leaders of these Christian communities need to consider to better support young Christian women? Do young Christian women find value in studying theology, history, and hermeneutics from female perspectives, and if so, why? These are the guiding questions this project seeks to answer. This project involves a qualitative research study with a group of students within a “Women in Christianity” course at Seattle Pacific University. Participants were interviewed twice during the course and also forwarded their written reflections to the researcher. Participants were asked to reflect on their experiences of being a Christian woman, experiences of sexism within Christian communities, and experiences within the course. The process of the research is a grounded theory study, in which the participants’ process throughout the class was used to narrate the progress of what is helpful to support and empower ones’ faith as a young Christian woman. Participants affirmed that there is deep value for young Christian women in studying theology, history, and hermeneutics from female perspectives. The knowledge gained helps young Christian women feel empowered, supported, and encouraged in their faith. This knowledge also performs a disruptive role, helping these women question the patriarchal culture they have previously experienced as “normal.” However, in order for any practices, traditions, or strategies to be effective in helping young Christian women sustain their faith and navigate sexism, Christian communities must become an active participant in working through methods of reconciliation to and for these women. Christian leaders would benefit from representing, including, and following methods laid out by women and for women, which are elaborated on within this project

Testing Accuracy and Convergence of GPUSPH for Free-Surface Flows

The effect of vegetation on the dissipation of waves is important in understanding the vegetation's role in protecting coastal communities during extreme events such as hurricanes and tsunamis. Numerical modeling makes it possible to study the flow through vegetation fields, but it is important to understand the flow dynamics around one piece of vegetation and validate the numerical model used, before the dynamics of an entire vegetated patch can be modeled and understood. This project validated GPUSPH, a Lagrangian mesh-free numerical model, by determining the optimal characteristics to obtain accurate simulations for flow through a flume with and without an obstruction. The validation of GPUSPH and determination of optimal characteristics was accomplished by varying model particle spacing, sub-particle scale (SPS) turbulence inclusion in the conservation of momentum equation, and kernel weighting function for two test cases. The model particle spacing sets the initial distance between the moving grid points, known as particles, in the system. The SPS turbulence term is intended to account for turbulence generated at the sub-particle scale between the particles. The kernel weighting functions used are the quadratic kernel and the cubic spline kernel. These kernels determine how much influence surrounding particles have on the flow characteristics of an individual particle. The numerical results of these tests were compared with experimental results to obtain conclusions about the accuracy of these simulations. Based on comparisons with experimental velocities and forces, the optimal particle spacing was found to occur when the number of particles was in the high 100,000s for single precision calculations, or mid-range capabilities, for the hardware used in this project. The sub-particle scale turbulence term was only necessary when there was large-scale turbulence in the system and created less accurate results when there was no large-scale turbulence present. There was no definitive conclusion regarding the best kernel weighting function because neither kernel had overall more accurate results than the other. Based on these conclusions, GPUSPH was shown to be a viable option for modeling free-surface flows for certain conditions concerning the particle spacing and the inclusion of the subparticle scale turbulence term

The Impact of Freeze-Thaw Cycles to the Physical and Biogeochemical Properties of Alaskan Permafrost Soils

Arctic warming is exposing thawing permafrost to repeated freeze-thaw, a disruptive process that can alter soil biogeochemistry and physical structure. To investigate the impact of permafrost exposure to freeze-thaw, soil response was tested across three scales: 2.5 cm³ aggregates, a forested hillslope, and two sites at contrasting latitudes. XCT imaging was employed to investigate pore deformation while FT-ICR-MS informed comparisons of carbon chemistry at the soil horizon, hillslope, and site levels. The initial stages of pore-scale freeze-thaw deformation following permafrost thaw resulted in decreasing connectivity and both expansion and collapse of pore throats with potential ramifications for spatial access to carbon and water holding capacity. At the hillslope scale, canopy-driven differences in soil temperature and carbon decomposition were more prevalent in conditions with lower moisture and thinner organic mats compared with high-moisture downslope soils. Across sites with differing freeze-thaw histories, there was greater oxidation of carbon molecules and loss of aliphatics following experimental freeze-thaw at the lower latitude site. Our findings indicate that factors such as freeze-thaw history, moisture, and organic mat thickness may influence carbon response to warming in permafrost soils, resulting in a heterogeneous response to freeze-thaw at both the site and hillslope scale

Developmental Dysfunction of the Central Nervous System Lymphatics Modulates the Adaptive Neuro-Immune Response in the Perilesional Cortex in a Mouse Model of Traumatic Brain Injury

Rationale The recently discovered meningeal lymphatic vessels (mLVs) have been proposed to be the missing link between the immune and the central nervous system. The role of mLVs in modulating the neuro-immune response following a traumatic brain injury (TBI), however, has not been analyzed. Parenchymal T lymphocyte infiltration has been previously reported as part of secondary events after TBI, suggestive of an adaptive neuro-immune response. The phenotype of these cells has remained mostly uncharacterized. In this study, we identified subpopulations of T cells infiltrating the perilesional areas 30 days post-injury (an early-chronic time point). Furthermore, we analyzed how the lack of mLVs affects the magnitude and the type of T cell response in the brain after TBI. Methods TBI was induced in K14-VEGFR3-Ig transgenic (TG) mice or in their littermate controls (WT; wild type), applying a controlled cortical impact (CCI). One month after TBI, T cells were isolated from cortical areas ipsilateral or contralateral to the trauma and from the spleen, then characterized by flow cytometry. Lesion size in each animal was evaluated by MRI. Results In both WT and TG-CCI mice, we found a prominent T cell infiltration in the brain confined to the perilesional cortex and hippocampus. The majority of infiltrating T cells were cytotoxic CD8+ expressing a CD44(hi)CD69+ phenotype, suggesting that these are effector resident memory T cells. K14-VEGFR3-Ig mice showed a significant reduction of infiltrating CD4+ T lymphocytes, suggesting that mLVs could be involved in establishing a proper neuro-immune response. Extension of the lesion (measured as lesion volume from MRI) did not differ between the genotypes. Finally, TBI did not relate to alterations in peripheral circulating T cells, as assessed one month after injury. Conclusions Our results are consistent with the hypothesis that mLVs are involved in the neuro-immune response after TBI. We also defined the resident memory CD8+ T cells as one of the main population activated within the brain after a traumatic injury.Peer reviewe

A coupled microscopy approach to assess the nano-landscape of weathering

Mineral weathering is a balanced interplay among physical, chemical, and biological processes. Fundamental knowledge gaps exist in characterizing the biogeochemical mechanisms that transform microbe-mineral interfaces at submicron scales, particularly in complex field systems. Our objective was to develop methods targeting the nanoscale by using high-resolution microscopy to assess biological and geochemical drivers of weathering in natural settings. Basalt, granite, and quartz (53-250 mu m) were deployed in surface soils (10 cm) of three ecosystems (semiarid, subhumid, humid) for one year. We successfully developed a reference grid method to analyze individual grains using: (1) helium ion microscopy to capture micron to sub-nanometer imagery of mineral-organic interactions; and (2) scanning electron microscopy to quantify elemental distribution on the same surfaces via element mapping and point analyses. We detected locations of biomechanical weathering, secondary mineral precipitation, biofilm formation, and grain coatings across the three contrasting climates. To our knowledge, this is the first time these coupled microscopy techniques were applied in the earth and ecosystem sciences to assess microbe-mineral interfaces and in situ biological contributors to incipient weathering.Oregon State University faculty startup fund; Office of Biological and Environmental Research; NSF [EAR-GEO-1331846, EAR-0724958, IOS-1354219]; [EAR-1023215]Open access journalThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

Significance of developmental meningeal lymphatic dysfunction in experimental post-traumatic injury

Publisher Copyright: © 2022 The AuthorsPeer reviewe

Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed by the Clinical Genome Resource

Supplemental Data Supplemental Data include 65 figures and can be found with this article online at http://dx.doi.org/10.1016/j.ajhg.2017.04.015. Supplemental Data Document S1. Figures S1–S65 Download Document S2. Article plus Supplemental Data Download Web Resources ClinGen, https://www.clinicalgenome.org/ ClinGen Gene Curation, https://www.clinicalgenome.org/working-groups/gene-curation/ ClinGen Gene Curation SOP, https://www.clinicalgenome.org/working-groups/gene-curation/projects-initiatives/gene-disease-clinical-validity-sop/ ClinGen Knowledge Base, https://search.clinicalgenome.org/kb/agents/sign_up OMIM, http://www.omim.org/ Orphanet, http://www.orpha.net/consor/cgi-bin/index.php With advances in genomic sequencing technology, the number of reported gene-disease relationships has rapidly expanded. However, the evidence supporting these claims varies widely, confounding accurate evaluation of genomic variation in a clinical setting. Despite the critical need to differentiate clinically valid relationships from less well-substantiated relationships, standard guidelines for such evaluation do not currently exist. The NIH-funded Clinical Genome Resource (ClinGen) has developed a framework to define and evaluate the clinical validity of gene-disease pairs across a variety of Mendelian disorders. In this manuscript we describe a proposed framework to evaluate relevant genetic and experimental evidence supporting or contradicting a gene-disease relationship and the subsequent validation of this framework using a set of representative gene-disease pairs. The framework provides a semiquantitative measurement for the strength of evidence of a gene-disease relationship that correlates to a qualitative classification: “Definitive,” “Strong,” “Moderate,” “Limited,” “No Reported Evidence,” or “Conflicting Evidence.” Within the ClinGen structure, classifications derived with this framework are reviewed and confirmed or adjusted based on clinical expertise of appropriate disease experts. Detailed guidance for utilizing this framework and access to the curation interface is available on our website. This evidence-based, systematic method to assess the strength of gene-disease relationships will facilitate more knowledgeable utilization of genomic variants in clinical and research settings

The ClinGen Epilepsy Gene Curation Expert Panel—Bridging the divide between clinical domain knowledge and formal gene curation criteria

The field of epilepsy genetics is advancing rapidly and epilepsy is emerging as a frequent indication for diagnostic genetic testing. Within the larger ClinGen framework, the ClinGen Epilepsy Gene Curation Expert Panel is tasked with connecting two increasingly separate fields: the domain of traditional clinical epileptology, with its own established language and classification criteria, and the rapidly evolving area of diagnostic genetic testing that adheres to formal criteria for gene and variant curation. We identify critical components unique to the epilepsy gene curation effort, including: (a) precise phenotype definitions within existing disease and phenotype ontologies; (b) consideration of when epilepsy should be curated as a distinct disease entity; (c) strategies for gene selection; and (d) emerging rules for evaluating functional models for seizure disorders. Given that de novo variants play a prominent role in many of the epilepsies, sufficient genetic evidence is often awarded early in the curation process. Therefore, the emphasis of gene curation is frequently shifted toward an iterative precuration process to better capture phenotypic associations. We demonstrate that within the spectrum of neurodevelopmental disorders, gene curation for epilepsy-associated genes is feasible and suggest epilepsy-specific conventions, laying the groundwork for a curation process of all major epilepsy-associated genes

The Human Phenotype Ontology project:linking molecular biology and disease through phenotype data

The Human Phenotype Ontology (HPO) project, available at http://www.human-phenotype-ontology.org, provides a structured, comprehensive and well-defined set of 10,088 classes (terms) describing human phenotypic abnormalities and 13,326 subclass relations between the HPO classes. In addition we have developed logical definitions for 46% of all HPO classes using terms from ontologies for anatomy, cell types, function, embryology, pathology and other domains. This allows interoperability with several resources, especially those containing phenotype information on model organisms such as mouse and zebrafish. Here we describe the updated HPO database, which provides annotations of 7,278 human hereditary syndromes listed in OMIM, Orphanet and DECIPHER to classes of the HPO. Various meta-attributes such as frequency, references and negations are associated with each annotation. Several large-scale projects worldwide utilize the HPO for describing phenotype information in their datasets. We have therefore generated equivalence mappings to other phenotype vocabularies such as LDDB, Orphanet, MedDRA, UMLS and phenoDB, allowing integration of existing datasets and interoperability with multiple biomedical resources. We have created various ways to access the HPO database content using flat files, a MySQL database, and Web-based tools. All data and documentation on the HPO project can be found online

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707